Continuous hormone replacement therapy with estradiol valerate and chlormadinone acetate in adjustable dosages. A preliminary study.
A group of 62 peri- and postmenopausal women suffering from vasomotor disturbances and a variety of other symptoms were treated with estradiol valerate and chlormadinone acetate continuously using an adjustable dosage regimen. They obtained complete relief from vasomotor symptoms. The continuation rate was 81% after 1 year. In 18 patients the dose had to be adjusted because of breakthrough bleeding (n = 12), mastodynia (n = 3), and for the prevention of bone loss. In 11/12 patients breakthrough bleeding could be stopped by adjusting the dosage. This regimen seems to offer a more flexible approach to hormone replacement therapy (HRT) in the postmenopause than presently available combined preparations for continuous use.
Rauch
U
U
Department of Obstetrics and Gynecology, Johann-Wolfgang-Goethe-University, Frankfurt am Main, Germany.
Taubert
H D
HD
D000328:Adult; D002715:Chlormadinone Acetate / Q000008:administration & dosage* / Q000009:adverse effects; D002979:Climacteric; D004958:Estradiol / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D015914:Estrogen Replacement Therapy / Q000009:adverse effects; D004966:Estrogens, Conjugated (USP) / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D008875:Middle Aged; D017698:Postmenopause
D004966:Estrogens, Conjugated (USP); D002715:Chlormadinone Acetate; D004958:Estradiol